Key Events This Week
1 June: Stock opens sharply lower at Rs.402.00 (-5.37%) amid broad market weakness
2 June: New 52-week high of Rs.440.15 and all-time high of Rs.429.35; hits upper circuit with 8.82% gain
3 June: Further new 52-week and all-time high at Rs.447.35 despite Sensex decline
4 June: Continued gains to Rs.456.85 (+3.97%) on moderate volume
5 June: Profit-taking leads to 4.12% decline, closing at Rs.438.05
1 June 2026: Sharp Opening Decline Amid Market Weakness
Bliss GVS Pharma Ltd opened the week at Rs.402.00, down 5.37% from the previous close of Rs.424.80. This decline coincided with a broader market sell-off as the Sensex fell 0.96% to 35,077.62. The stock’s volume was robust at 185,021 shares, reflecting active trading interest despite the negative sentiment. The drop appeared to be a reaction to general market pressures rather than company-specific news.
2 June 2026: Breakout to New Highs and Upper Circuit Surge
On 2 June, Bliss GVS Pharma Ltd staged a remarkable recovery, surging 8.15% to close at Rs.434.75. The stock hit a new 52-week high of Rs.440.15 and an all-time intraday high of Rs.429.35, signalling strong bullish momentum. Notably, the stock hit its upper circuit limit with an 8.82% gain, closing at Rs.437.95, driven by robust buying interest and a turnover of approximately ₹146.84 crore. This rally significantly outperformed the Sensex, which rose modestly by 0.43% to 35,227.64.
Technical indicators were strongly positive, with the stock trading above all key moving averages and supported by bullish MACD and KST oscillators. Delivery volumes increased substantially, indicating genuine investor participation. The company’s Mojo Score remained at 64.0, reflecting a Hold rating upgraded from Sell in November 2025.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
3 June 2026: Continued Rally to New 52-Week and All-Time High
Bliss GVS Pharma Ltd extended its gains on 3 June, reaching a fresh 52-week and all-time high of Rs.447.35. The stock closed at Rs.439.40, up 1.07% on the day, despite the Sensex falling 0.34% to 35,107.33. This marked the second consecutive day of strong performance, with a cumulative two-day gain of 9% from the previous close.
Technical momentum remained robust, supported by bullish MACD, Bollinger Bands, and KST indicators on weekly and monthly charts. The stock continued to trade above all major moving averages, reinforcing its positive trend. Valuation multiples as of this date showed a P/E ratio of 35 times TTM earnings and a PEG ratio of 0.65, indicating growth at a premium but supported by earnings expansion.
Financial metrics highlighted strong recent quarterly results with a 128.8% increase in PAT to ₹35.56 crores and record net sales of ₹256.99 crores. The company maintained a low debt-to-equity ratio of 0.02 times and a high ROCE of 16.80% for the half-year period, underscoring financial discipline and operational strength.
4 June 2026: Further Gains on Moderate Volume
The stock continued its upward trajectory on 4 June, closing at Rs.456.85, a 3.97% gain. Volume was lower at 100,402 shares, suggesting some consolidation after the prior days’ strong rallies. The Sensex rose marginally by 0.19% to 35,175.61, but Bliss GVS Pharma Ltd outperformed the benchmark significantly. The stock’s technical indicators remained positive, with the price well above key moving averages.
Holding Bliss GVS Pharma Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
5 June 2026: Profit-Taking Leads to Moderate Decline
On the final trading day of the week, Bliss GVS Pharma Ltd experienced profit-taking pressure, closing at Rs.438.05, down 4.12% from the previous day’s close. Volume was the lowest of the week at 76,119 shares. The Sensex also declined slightly by 0.10% to 35,141.95. Despite the pullback, the stock maintained a weekly gain of 3.12%, reflecting overall strength relative to the benchmark.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-06-01 | Rs.402.00 | -5.37% | 35,077.62 | -0.96% |
| 2026-06-02 | Rs.434.75 | +8.15% | 35,227.64 | +0.43% |
| 2026-06-03 | Rs.439.40 | +1.07% | 35,107.33 | -0.34% |
| 2026-06-04 | Rs.456.85 | +3.97% | 35,175.61 | +0.19% |
| 2026-06-05 | Rs.438.05 | -4.12% | 35,141.95 | -0.10% |
Key Takeaways from the Week
Strong Relative Performance: Bliss GVS Pharma Ltd outperformed the Sensex by 3.90 percentage points over the week, demonstrating resilience amid a broadly weak market.
Multiple New Highs: The stock hit new 52-week and all-time highs on 2 and 3 June, reflecting sustained buying interest and positive technical momentum.
Robust Financials: Recent quarterly results showed strong profit growth and record sales, supported by a healthy balance sheet with minimal debt and high ROCE.
Technical Strength: The stock consistently traded above all major moving averages, with bullish MACD and KST indicators reinforcing the positive trend.
Volatility and Profit-Taking: The upper circuit hit on 2 June and the subsequent profit-taking on 5 June highlight the stock’s volatility and the need for cautious monitoring.
Conclusion
Bliss GVS Pharma Ltd’s performance during the week of 1 to 5 June 2026 was marked by strong gains and multiple record highs, supported by robust financial results and positive technical indicators. Despite a challenging broader market environment, the stock’s outperformance and sustained momentum underscore its distinct trajectory within the Pharmaceuticals & Biotechnology sector. Investors should note the volatility observed midweek and the profit-taking towards the week’s close, suggesting a balanced approach is prudent when assessing this micro-cap stock’s near-term prospects.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
